Feed GMAB
GM

Genmab A/S GMAB · NASDAQ

$57.06 +1.01% (+$0.57)

Market cap
$34.7B
Enterprise value
$38.5B
P/E
44.1x
Forward P/E
42.2x
PEG
-
P/S
8.4x
P/FCF
40.0x
EV/EBITDA
31.6x
ROIC
9.9%
Gross margin
93.0%
Net margin
19.1%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
3.1x
Beta
0.65
Free float
95.5%

About the company

Genmab A/S (GMAB) is a Danish biotechnology company specializing in the research, development, and manufacturing of monoclonal antibodies for the treatment of various types of cancer and immune-related diseases. The company is known for its innovative approaches to therapies and a robust portfolio of therapeutic antibodies undergoing clinical trials. Genmab focuses on collaborations with pharmaceutical partners and leverages its advanced technology to create medicines with the potential to revolutionize the way diseases are treated. Genmab A/S (GMAB) shares might appeal to investors seeking exponential growth in the biotechnology sector.

Sector

Healthcare

Industry

Biotechnology

CEO

Jan van de Winkel

Employees

3,119

Headquarters

Copenhagen

Valuation

Is today's price reasonable?

  • What to watch: You pay 44.1 USD for 1 USD of yearly profit, a lot for its sector.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Analysts expect revenue to grow by 20% this fiscal year.
  • What to watch: Revenue fell by 36% a year over the last 3 years.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 USD of revenue, 19 USD is left as net profit.

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy